

JUN. 22. 2004 2:35PM

SANOFI PATENTS

NO. 5826 P. 1

Sanofi-Synthelabo Research
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355

sanofi-synthelabo**FAX COVER SHEET**

DATE: June 22, 2004 # OF PAGES: 7

TO: Office of Initial Patent Examination's PHONE#:
Filing Receipt Corrections
USPTO FAX#: 1-703-746-9195

FROM: Paul E. Dupont PHONE#: 610-889-6338
Sanofi-Synthelabo FAX#: 610-889-8799

cc: FAX#:

RE: Serial No. 10/810,109 (Atty. Docket IVD 938-2)

If you have any problems receiving this message, please call (610) 889-6306

◆ MESSAGE ◆**Attached are the following:**

- Request for Corrected Filing Receipt
- Filing Receipt showing corrections
- Declaration and Power of Attorney (copy)

IMPORTANT: THE INFORMATION IN THIS FACSIMILE TRANSMISSION BELONGS TO SANOFI PHARMACEUTICALS, INC., IS INTENDED FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR USE OF, OR RELIANCE ON, THE CONTENTS OF THIS FACSIMILE TRANSMISSION IS PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE TRANSMISSION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE TO ARRANGE FOR THE RETURN OF THE ENTIRE FACSIMILE TRANSMISSION, INCLUDING ANY COPIES THEREOF, TO SANOFI PHARMACEUTICALS, INC. THANK YOU.

BEST AVAILABLE COPY

Docket No. IVD 938-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Bach et al.

Serial No.: 10/810,109

Filed: March 26, 2004

Group Art Unit: 1646

Preliminary Class: 424

For: USE OF IL-7 FOR TREATING AUTOIMMUNE
DISEASES, IN PARTICULAR INSULIN-DEPENDENT
DIABETES MELLITUSCERTIFICATE OF FACSIMILE TRANSMISSIONI hereby certify that this correspondence is being facsimile
transmitted on the date indicated below to the United States
Patent and Trademark OfficeAttn: Office of Initial Patent Examination's Customer
Service Center

Fax No. 703-746-9195

Name

Date

Commissioner for Patents
Office of Initial Patent Examination's
Customer Service Center
Washington, DC 20231

Dear Sir:

REQUEST FOR CORRECTED FILING RECEIPTAttention is called to errors in the Filing Receipt for the above-identified application. A copy of the Filing
Receipt showing the following correction is enclosed herewith.

The following inventor's name is misspelled and should read as follows:

Jean Marc GombertApplicants residences were provided on the copy of the Declaration from the parent case and should read as
follows:Jean Francois Bach, Paris, France
Jean Marc Gombert, Poitiers, France
Andre Herbelin, Malakoff, France
Michel Morre, Boulogne, France

Please see attached copy of Declaration with each Applicant's residence circled.

In view of the foregoing, Applicants respectfully request issuance of a corrected filing receipt for the above-
identified application.

Date:

Respectfully submitted,

Paul E. Dupont
Reg. No. 27,438Address:
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Tele: (610) 889-6338
Facsimile: (610) 889-8799



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1420
Alexandria, Virginia 22313-1420
www.uspto.gov


APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/810,109	03/26/2004	1646	770	IVD 938-2	2	16	3

REC'D JUN 14 2004

CONFIRMATION NO. 8031

27546
SANOFI-SYNTHELABO INC.
9 GREAT VALLEY PARKWAY
P.O. BOX 3026
MALVERN, PA 19355

FILING RECEIPT



OC000000012965137

ENTERED
1-14-04

Date Mailed: 06/07/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jean Francois Bach, Residence Not Provided; Paris, FRANCE
Marc ← Jean Marc Gombert, Residence Not Provided; Poitiers, FRANCE
Andre Herbelin, Residence Not Provided; Malakoff, FRANCE
Michel Morre, Residence Not Provided; Boulogne, FRANCE

Domestic Priority data as claimed by applicant

This application is a DIV of 09/125,168 08/18/1998 PAT 6,713,053
which is a 371 of PCT/FR97/00343 02/26/1997

Foreign Applications

FRANCE FR 96 02501 02/28/1996

If Required, Foreign Filing License Granted: 06/05/2004

Projected Publication Date: 09/16/2004

Non-Publication Request: No

Early Publication Request: No

Title

Use of IL-7 for treating autoimmune diseases, in particular insulin-dependent diabetes mellitus

Preliminary Class

424

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).